CTOs on the Move

Vifor Pharma

www.viforpharma.com

 
Vifor Pharma is a Basking Ridge, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Clearside Biomedical

Clearside Biomedical, Inc. is a clinical-stage biopharmaceutical company developing first-in-class drug therapies to treat chronic, blinding diseases of the eye.

Prasco Laboratories

Prasco Laboratories is a Mason, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Shiel Medical Laboratories

Shiel offers a comprehensive menu of test and diagnostic options through participating physicians and health care providers, and through our ever expanding Patient Service Center Network. Our full-service in-house pathology department performs GYN (Pap

Western Allergy Services

Western Allergy Services Ltd is a Victoria, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Unum Therapeutics

Unum is a Cambridge, MA-based cellular therapeutics company ushering in a new wave of innovation in cancer immunotherapy. Unum has built an antibody-coupled T-cell receptor (ACTR) platform that, when combined with tumor-specific antibodies, directs an individual’s cytotoxic T-lymphocytes (CTLs) to kill tumor cells. In contrast to other approaches that hit a single target and treat a narrow set of tumors, Unum’s approach is not restricted by antigens and may have applications for treating many types of cancers.   Our lead program based on ACTR technology is expected to enter Phase I clinical testing soon to assess safety and efficacy in certain forms of leukemia and lymphoma. In parallel, we are actively seeking partners interested in using the ACTR technology to arm novel proprietary antibodies with a T-cell to improve their therapeutic potential. Working initially to pre-clinically validate antibody-ACTR combinations with partners, we expect to rapidly advance multiple proprietary combinations into clinical testing within the next few years.